AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia
THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.
The acquisition adds to Amgen's portfolio an investigational small molecule that targets and degrades two proteins (MLLT1/3) that drive specific types of acute myeloid leukemia (AML), a fast-growing blood cancer. Preclinical data in leukemia models demonstrate promisi
